PRMT5 Methylates and Stabilizes EphA2 via Inhibiting Its Ubiquitination and Degradation to Promote Nasopharyngeal Carcinoma Stem Cell Properties

Abstract

Both PRMT5 and EphA2 proteins are overexpressed and play a crucial role in multiple cancers, and have been used as targets to develop new anticancer drugs. However, the function and significance of the PRMT5–EphA2 interaction are unclear. Here, we report that PRMT5 bound to EphA2, catalyzed the dimethylation of EphA2 at arginine 816, and then stabilized EphA2 via inhibiting Cbl-mediated EphA2 ubiquitination and degradation in nasopharyngeal carcinoma (NPC) cells. Functionally, PRMT5 promoted in vitro and in vivo NPC stem cell properties by methylating and stabilizing EphA2. Based on the interacting regions of PRMT5 and EphA2 proteins, we developed a 20 amino acid-long PRMT5-derived peptide, P20, which disrupted the connection of PRMT5 with EphA2, degraded EphA2, and suppressed NPC stem cell properties in vitro and in mice. Moreover, the expression levels of PRMT5 and EphA2 in the NPC tissues were significantly higher than those in the normal nasopharyngeal mucosal tissues, and both proteins for predicting the patient's prognosis are superior to individual proteins. Our findings suggest that PRMT5 methylates and stabilizes EphA2 to promote NPC stem cell properties, and the PRMT5-derived peptide P20 can serve as a novel strategy for targeting EphA2 degradation and inhibiting NPC stem cell properties.

Keywords

cancer stemness / EphA2 / nasopharyngeal carcinoma / PRMT5 / protein–protein interaction / therapeutic peptide

References

[1] M. T. Bedford and S. G. Clarke, “Protein Arginine Methylation in Mammals: Who, What, and Why,” Molecular Cell 33, no. 1 (2009): 1–13, https://doi.org/10.1016/j.molcel.2008.12.013.

[2] R. S. Blanc and S. Richard, “Arginine Methylation: The Coming of Age,” Molecular Cell 65, no. 1 (2017): 8–24.

[3] N. Stopa, J. E. Krebs, and D. Shechter, “The PRMT5 Arginine Methyltransferase: Many Roles in Development, Cancer and Beyond,” Cellular and Molecular Life Sciences 72, no. 11 (2015): 2041–2059.

[4] L. T. Sun, M. Z. Wang, Z. Y. Lv, et al., “Structural Insights Into Protein Arginine Symmetric Dimethylation by PRMT5,” PNAS USA 108, no. 51 (2011): 20538–20543.

[5] Y. Z. Yang and M. T. Bedford, “Protein Arginine Methyltransferases and Cancer,” Nature Reviews Cancer 13, no. 1 (2013): 37–50.

[6] D. Hu, M. Gur, Z. Zhou, et al., “Interplay Between Arginine Methylation and Ubiquitylation Regulates KLF4-mediated Genome Stability and Carcinogenesis,” Nature Communications 6 (2015): 8419.

[7] M. Mei, R. Zhang, Z. W. Zhou, et al., “PRMT5-mediated H4R3sme2 Confers Cell Differentiation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia,” Clinical Cancer Research 25, no. 8 (2019): 2633–2643.

[8] J. M. Hsu, C. T. Chen, C. K. Chou, et al., “Crosstalk Between Arg 1175 Methylation and Tyr 1173 Phosphorylation Negatively Modulates EGFR-Mediated ERK Activation,” Nature Cell Biology 13, no. 2 (2011): 174–181.

[9] A. Liu, C. Yu, C. Qiu, et al., “PRMT5 Methylating SMAD4 Activates TGF-Beta Signaling and Promotes Colorectal Cancer Metastasis,” Oncogene 42, no. 19 (2023): 1572–1584.

[10] Z. Wang, R. Li, N. Hou, et al., “PRMT5 Reduces Immunotherapy Efficacy in Triple-Negative Breast Cancer by Methylating KEAP1 and Inhibiting Ferroptosis,” Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006890.

[11] A. Chittka, J. Nitarska, U. Grazini, and W. D. Richardson, “Transcription Factor Positive Regulatory Domain 4 (PRDM4) Recruits Protein Arginine Methyltransferase 5 (PRMT5) to Mediate Histone Arginine Methylation and Control Neural Stem Cell Proliferation and Differentiation,” Journal of Biological Chemistry 287, no. 51 (2012): 42995–43006.

[12] J. DeSisto, I. Balakrishnan, A. J. Knox, et al., “PRMT5 Maintains Tumor Stem Cells to Promote Pediatric High-Grade Glioma Tumorigenesis,” Molecular Cancer Research 23, no. 2 (2025): 107–118.

[13] X. Wang, T. Qiu, Y. Wu, et al., “Arginine Methyltransferase PRMT5 Methylates and Stabilizes KLF5 via Decreasing Its Phosphorylation and Ubiquitination to Promote Basal-Like Breast Cancer,” Cell Death and Differentiation 28, no. 10 (2021): 2931–2945.

[14] Y. Jin, J. Zhou, F. Xu, et al., “Targeting Methyltransferase PRMT5 Eliminates Leukemia Stem Cells in Chronic Myelogenous Leukemia,” Journal of Clinical Investigation 126, no. 10 (2016): 3961–3980.

[15] J. Zheng, B. Li, Y. Wu, X. Wu, and Y. Wang, “Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies,” Journal of Medicinal Chemistry 66, no. 13 (2023): 8407–8427.

[16] E. B. Pasquale, “Eph-ephrin Bidirectional Signaling in Physiology and Disease,” Cell 133, no. 1 (2008): 38–52.

[17] H. Miao, D. Q. Li, A. Mukherjee, et al., “EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop With Akt,” Cancer Cell 16, no. 1 (2009): 9–20.

[18] L. Fattet, H. Y. Jung, M. W. Matsumoto, et al., “Matrix Rigidity Controls Epithelial–Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex,” Developmental Cell 54, no. 3 (2020): 302–316.e7.

[19] E. Binda, A. Visioli, F. Giani, et al., “The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-Like Tumor-Propagating Cells From human Glioblastomas,” Cancer Cell 22, no. 6 (2012): 765–780.

[20] W. Song, Y. Ma, J. Wang, D. Brantley-Sieders, and J. Chen, “JNK Signaling Mediates EPHA2-Dependent Tumor Cell Proliferation, Motility, and Cancer Stem Cell-Like Properties in Non-Small Cell Lung Cancer,” Cancer Research 74, no. 9 (2014): 2444–2454.

[21] M. Primeaux, X. Liu, S. Gowrikumar, et al., “Claudin-1 Interacts With EPHA2 to Promote Cancer Stemness and Chemoresistance in Colorectal Cancer,” Cancer Letters 579 (2023): 216479.

[22] J. Bai, Y. Chen, Y. Sun, et al., “EphA2 Promotes the Transcription of KLF4 to Facilitate Stemness in Oral Squamous Cell Carcinoma,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 278.

[23] J. Y. Li, T. Xiao, H. M. Yi, et al., “S897 Phosphorylation of EphA2 Is Indispensable for EphA2-dependent Nasopharyngeal Carcinoma Cell Invasion, Metastasis and Stem Properties,” Cancer Letters 444 (2019): 162–174.

[24] K. Wilson, E. Shiuan, and D. M. Brantley-Sieders, “Oncogenic Functions and Therapeutic Targeting of EphA2 in Cancer,” Oncogene 40, no. 14 (2021): 2483–2495.

[25] T. Xiao, Y. Xiao, W. Wang, Y. Y. Tang, Z. Xiao, and M. Su, “Targeting EphA2 in Cancer,” Journal of Hematology & Oncology 13, no. 1 (2020): 114.

[26] J. Feng, S. S. Lu, T. Xiao, et al., “ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis,” Cancer Research 80, no. 20 (2020): 4386–4398.

[27] V. V. Iyer, “A Review of Stapled Peptides and Small Molecules to Inhibit Protein–Protein Interactions in Cancer,” Current Medicinal Chemistry 23, no. 27 (2016): 3025–3043.

[28] L. G. Ferreira, G. Oliva, and A. D. Andricopulo, “Protein–Protein Interaction Inhibitors: Advances in Anticancer Drug Design,” Expert Opinion on Drug Discovery 11, no. 10 (2016): 957–968.

[29] L. Liang, H. Wang, H. Shi, et al., “A Designed Peptide Targets Two Types of Modifications of p53 With Anticancer Activity,” Cell Chemical Biology 25, no. 6 (2018): 761–774.

[30] Z. Z. Yu, Y. Y. Liu, W. Zhu, et al., “ANXA1-Derived Peptide for Targeting PD-L1 Degradation Inhibits Tumor Immune Evasion in Multiple Cancers,” Journal for ImmunoTherapy of Cancer 11, no. 3 (2023): e006345.

[31] Y. P. Chen, A. T. C. Chan, Q. T. Le, P. Blanchard, Y. Sun, and J. Ma, “Nasopharyngeal Carcinoma,” Lancet 394, no. 10192 (2019): 64–80.

[32] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature 414, no. 6859 (2001): 105–111.

[33] N. Zhu, Q. Wang, Z. Wu, Y. Wang, M. S. Zeng, and Y. Yuan, “Epstein–Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties,” Journal of Virology 96, no. 5 (2022): e0194121.

[34] C. C. Deng, Y. Liang, M. S. Wu, et al., “Nigericin Selectively Targets Cancer Stem Cells in Nasopharyngeal Carcinoma,” International Journal of Biochemistry & Cell Biology 45, no. 9 (2013): 1997–2006.

[35] O. Sabet, R. Stockert, G. Xouri, Y. Brüggemann, A. Stanoev, and P. I. Bastiaens, “Ubiquitination Switches EphA2 Vesicular Traffic From a Continuous Safeguard to a Finite Signalling Mode,” Nature Communications 6 (2015): 8047.

[36] C. Naudin, A. Sirvent, C. Leroy, et al., “SLAP Displays Tumour Suppressor Functions in Colorectal Cancer via Destabilization of the SRC Substrate EPHA2,” Nature Communications 5 (2014): 3159.

[37] J. Fuhrmann, K. W. Clancy, and P. R. Thompson, “Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation,” Chemical Reviews 115, no. 11 (2015): 5413–5461.

[38] N. Qvit, S. J. S. Rubin, T. J. Urban, D. Mochly-Rosen, and E. R. Gross, “Peptidomimetic Therapeutics: Scientific Approaches and Opportunities,” Drug Discovery Today 22, no. 2 (2017): 454–462.

[39] F. Pastore, N. Bhagwat, A. Pastore, et al., “PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2(V617F)-Mutant MPN,” Cancer Discovery 10, no. 11 (2020): 1742–1757.

[40] S. AbuHammad, C. Cullinane, C. Martin, et al., “Regulation of PRMT5-MDM4 Axis Is Critical in the Response to CDK4/6 Inhibitors in Melanoma,” PNAS USA 116, no. 36 (2019): 17990–18000.

[41] M. Vieito, V. Moreno, A. Spreafico, et al., “Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors,” Clinical Cancer Research 29, no. 18 (2023): 3592–3602.

[42] D. Q. Tan, Y. Li, C. Yang, et al., “PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells,” Cell Reports 26, no. 9 (2019): 2316–2328.e6.

[43] A. Henninot, J. C. Collins, and J. M. Nuss, “The Current State of Peptide Drug Discovery: Back to the Future?,” Journal of Medicinal Chemistry 61 (2018): 1382–1414.

[44] K. B. Sylvestersen, H. Horn, S. Jungmichel, L. J. Jensen, and M. L. Nielsen, “Proteomic Analysis of Arginine Methylation Sites in Human Cells Reveals Dynamic Regulation During Transcriptional Arrest,” Molecular & Cellular Proteomics 13, no. 8 (2014): 2072–2088.

[45] C. E. Tang, Y. J. Guan, B. Yi, et al., “Identification of the Amyloid β-Protein Precursor and Cystatin C as Novel Epidermal Growth Factor Receptor Regulated Secretory Proteins in Nasopharyngeal Carcinoma by Proteomics,” Journal of Proteome Research 9, no. 12 (2010): 6101–6111.

[46] Z. Zheng, J. Q. Qu, H. M. Yi, et al., “MiR-125b Regulates Proliferation and Apoptosis of Nasopharyngeal Carcinoma by Targeting A20/NF-κB Signaling Pathway,” Cell Death & Disease 8, no. 6 (2017): e2855.

[47] D. Kozakov, D. R. Hall, B. Xia, et al., “The ClusPro Web Server for Protein–Protein Docking,” Nature Protocols 12, no. 2 (2017): 255–278.

[48] Y. Yan, H. Tao, J. He, and S. Y. Huang, “The HDOCK Server for Integrated Protein–Protein Docking,” Nature Protocols 15, no. 5 (2020): 1829–1852.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.